BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 9294131)

  • 1. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.
    Mahata SK; O'Connor DT; Mahata M; Yoo SH; Taupenot L; Wu H; Gill BM; Parmer RJ
    J Clin Invest; 1997 Sep; 100(6):1623-33. PubMed ID: 9294131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.
    Mahata SK; Mahata M; Wakade AR; O'Connor DT
    Mol Endocrinol; 2000 Oct; 14(10):1525-35. PubMed ID: 11043569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.
    Mahapatra NR; Mahata M; Mahata SK; O'Connor DT
    J Hypertens; 2006 May; 24(5):895-904. PubMed ID: 16612252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses.
    Mahata SK; Mahata M; Wen G; Wong WB; Mahapatra NR; Hamilton BA; O'Connor DT
    Mol Pharmacol; 2004 Nov; 66(5):1180-91. PubMed ID: 15326220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance.
    Mahata SK; Mahata M; Parmer RJ; O'Connor DT
    J Biol Chem; 1999 Jan; 274(5):2920-8. PubMed ID: 9915830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism.
    Taupenot L; Mahata SK; Mahata M; Parmer RJ; O'Connor DT
    Regul Pept; 2000 Nov; 95(1-3):9-17. PubMed ID: 11062327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.
    Lee JC; Taylor CV; Gaucher SP; Toneff T; Taupenot L; Yasothornsrikul S; Mahata SK; Sei C; Parmer RJ; Neveu JM; Lane WS; Gibson BW; O'Connor DT; Hook VY
    Biochemistry; 2003 Jun; 42(23):6938-46. PubMed ID: 12795588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A.
    Preece NE; Nguyen M; Mahata M; Mahata SK; Mahapatra NR; Tsigelny I; O'Connor DT
    Regul Pept; 2004 Apr; 118(1-2):75-87. PubMed ID: 14759560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis.
    Mahata SK; Mahata M; Yoo SH; Taupenot L; Wu H; Aroda VR; Livsey CV; Taulane JP; Goodman M; Parmer RJ; O'Connor DT
    Adv Pharmacol; 1998; 42():260-4. PubMed ID: 9327894
    [No Abstract]   [Full Text] [Related]  

  • 10. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
    Taupenot L; Mahata SK; Wu H; O'Connor DT
    J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364). Properties and function.
    Mahata SK; Mahata M; Livsey Taylor CV; Taupenot L; Parmer RJ; O'Connor DT
    Adv Exp Med Biol; 2000; 482():263-77. PubMed ID: 11192587
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity.
    Tsigelny I; Mahata SK; Taupenot L; Preece NE; Mahata M; Khan I; Parmer RJ; O'Connor DT
    Regul Pept; 1998 Oct; 77(1-3):43-53. PubMed ID: 9809795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.
    Mahata SK; Mahapatra NR; Mahata M; Wang TC; Kennedy BP; Ziegler MG; O'Connor DT
    J Biol Chem; 2003 Aug; 278(34):32058-67. PubMed ID: 12799369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proadrenomedullin N-terminal 20 peptide: minimal active region to regulate nicotinic receptors.
    Mahata M; Mahata SK; Parmer RJ; O'Connor DT
    Hypertension; 1998 Nov; 32(5):907-16. PubMed ID: 9822452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of cytosolic calcium entry and protein kinase C.
    Tang K; Wu H; Mahata SK; Mahata M; Gill BM; Parmer RJ; O'Connor DT
    J Clin Invest; 1997 Sep; 100(5):1180-92. PubMed ID: 9276735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A: a surprising link between granule biogenesis and hypertension.
    Kim T; Loh YP
    J Clin Invest; 2005 Jul; 115(7):1711-3. PubMed ID: 16007250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromostatin, a 20-amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion.
    Galindo E; Rill A; Bader MF; Aunis D
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1426-30. PubMed ID: 1996343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis.
    Herrero CJ; Alés E; Pintado AJ; López MG; García-Palomero E; Mahata SK; O'Connor DT; García AG; Montiel C
    J Neurosci; 2002 Jan; 22(2):377-88. PubMed ID: 11784782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
    Taylor CV; Taupenot L; Mahata SK; Mahata M; Wu H; Yasothornsrikul S; Toneff T; Caporale C; Jiang Q; Parmer RJ; Hook VY; O'Connor DT
    J Biol Chem; 2000 Jul; 275(30):22905-15. PubMed ID: 10781584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The catecholamine release-inhibitory peptide catestatin (chromogranin A344-363) modulates myocardial function in fish.
    Imbrogno S; Garofalo F; Cerra MC; Mahata SK; Tota B
    J Exp Biol; 2010 Nov; 213(Pt 21):3636-43. PubMed ID: 20952611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.